Press Releases

 ACTUATE THERAPEUTICS ANNOUNCES FIRST PATIENT ENROLLED IN PHASE 2 CLINICAL TRIAL OF ELRAGLUSIB PLUS RETIFANLIMAB AS INVESTIGATIONAL FIRST LINE THERAPY FOR PATIENTS WITH ADVANCED PANCREATIC CANCER 

 Elraglusib combination Phase 2 trial with retifanlimab based on observed synergy with immune checkpoint inhibitors, and preclinical and early clinical data supporting immunomodulatory activity of GSK-3β inhibitors  CHICAGO, IL and FORT WORTH, TX – March 1, 2022 – Actuate Therapeutics and The University of Kansas Cancer Center today announced the enrollment of the first patient …

 ACTUATE THERAPEUTICS ANNOUNCES FIRST PATIENT ENROLLED IN PHASE 2 CLINICAL TRIAL OF ELRAGLUSIB PLUS RETIFANLIMAB AS INVESTIGATIONAL FIRST LINE THERAPY FOR PATIENTS WITH ADVANCED PANCREATIC CANCER  Read More »

ACTUATE THERAPEUTICS ANNOUNCES INITIATION OF A MULTICENTER RANDOMIZED TRIAL OF ELRAGLUSIB PLUS FOLFIRINOX AS FIRST LINE THERAPY FOR ADVANCED PANCREATIC CANCER

Elraglusib will be combined with FOLFIRINOX alone or with Losartan in multi-centerPhase 2 clinical study initiated at Massachusetts General Hospital, Fred Hutchinson CancerResearch Center, University of Colorado, Denver, and Johns Hopkins University with studyfunding provided by the Lustgarten Foundation for Pancreatic Cancer Research CHICAGO, IL and FORT WORTH, TX – February 7, 2022 – Actuate …

ACTUATE THERAPEUTICS ANNOUNCES INITIATION OF A MULTICENTER RANDOMIZED TRIAL OF ELRAGLUSIB PLUS FOLFIRINOX AS FIRST LINE THERAPY FOR ADVANCED PANCREATIC CANCER Read More »

ACTUATE THERAPEUTICS ANNOUNCES PRIMARY ENDPOINT MET IN PHASE 2 STUDY IN PANCREATIC CANCER

Elraglusib Results in 57% Disease Control Rate and 39% Objective Response Rate inCombination with Gemcitabine/Abraxane in First Line Treatment of Pancreatic Cancer CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, today announced that their Phase 2 open-label single arm study of elraglusib (9-ING-41) plus gemcitabine/nab-paclitaxel treatment met …

ACTUATE THERAPEUTICS ANNOUNCES PRIMARY ENDPOINT MET IN PHASE 2 STUDY IN PANCREATIC CANCER Read More »

ACTUATE THERAPEUTICS ANNOUNCES FDA FAST TRACK DESIGNATION FOR 9-ING-41 FOR TREATMENT OF PANCREATIC CANCER

CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for 9-ING-41 for treatment of patients with pancreatic cancer. 9-ING-41 is Actuate’s proprietary small molecule glycogen synthase kinase-3 beta (GSK-3β) inhibitor which is being …

ACTUATE THERAPEUTICS ANNOUNCES FDA FAST TRACK DESIGNATION FOR 9-ING-41 FOR TREATMENT OF PANCREATIC CANCER Read More »

ACTUATE THERAPEUTICS ANNOUNCES INITIATION OF PHASE 2 CLINICAL STUDY IN PANCREATIC CANCER

CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, today announced enrollment of the first patients with first-line advanced pancreatic cancer in a phase 2 study of 9-ING-41, as a new arm of the ongoing phase 1/2 1801 trial of 9-ING-41, (NCT03678883, EudraCT#:2018-003739-32). 9-ING-41 is Actuate’s proprietary small …

ACTUATE THERAPEUTICS ANNOUNCES INITIATION OF PHASE 2 CLINICAL STUDY IN PANCREATIC CANCER Read More »

ACTUATE THERAPEUTICS ANNOUNCES 9-ING-41 DATA PRESENTATION AT ASCO ANNUAL MEETING 2020

CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, announced today that interim results from their 1801 Phase 1/2 study (NCT03678883, EudraCT #: 2018-003739-32) will be presented at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting which will take place virtually on May 29th, 2020. Dr. …

ACTUATE THERAPEUTICS ANNOUNCES 9-ING-41 DATA PRESENTATION AT ASCO ANNUAL MEETING 2020 Read More »

ACTUATE THERAPEUTICS ANNOUNCES INITIATION OF ADDITIONAL CLINICAL STUDIES FOR 9-ING-41

CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, today announced the initiation of two additional clinical studies with its lead molecule, 9-ING-41, a Glycogen Synthase Kinase beta (GSK-3β) inhibitor. On April 8, the company opened its 1902 study: A Phase 1 study of 9-ING-41, a Glycogen Synthase …

ACTUATE THERAPEUTICS ANNOUNCES INITIATION OF ADDITIONAL CLINICAL STUDIES FOR 9-ING-41 Read More »

ACTUATE THERAPEUTICS COMPLETES $6.5 MILLION SERIES B-3 FINANCING TO EXPAND CLINICAL PROGRAMS

CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc., a clinical stage biopharmaceutical company, today announced it has raised an additional $6.5M in a Series B-3 financing round. This Series B-3 was led by Bios Partners with Kairos Ventures, DEFTA Partners, and other existing investors participating, and brings total funding for Actuate’s Series B …

ACTUATE THERAPEUTICS COMPLETES $6.5 MILLION SERIES B-3 FINANCING TO EXPAND CLINICAL PROGRAMS Read More »

ACTUATE THERAPEUTICS COMPLETES $21.7 MILLION SERIES B FINANCING

CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc., a clinical stage biopharmaceutical company, today announced it has raised $21.7 Million in a Series B financing round. The Series B is led by Kairos Ventures, with DEFTA Partners, Tech Coast Angels, and existing investors, Bios Partners, participating. Actuate will use the proceeds of the …

ACTUATE THERAPEUTICS COMPLETES $21.7 MILLION SERIES B FINANCING Read More »

ACTUATE THERAPEUTICS OPENS PHASE 1 / 2 CLINICAL STUDY OF 9-ING-41 IN PATIENTS WITH REFRACTORY CANCERS

CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc., a clinical stage biopharmaceutical company, today announced the enrollment of the first patients in its 1801 Phase 1 / 2 study of 9-ING-41, a proprietary glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in patients with refractory hematologic malignancies or solid tumors. “Opening enrollment on our first …

ACTUATE THERAPEUTICS OPENS PHASE 1 / 2 CLINICAL STUDY OF 9-ING-41 IN PATIENTS WITH REFRACTORY CANCERS Read More »